Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
John Blessing
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Concepts & Ideas
Activities & Behaviors
Procedures
Physiology
Sign-in to see full Profile
Network (preview)
18
Sutton, GP
16
Homesley, Howard
14
Look, Katherine
11
Rose, Peter
8
Mannel, Robert
8
Miller, David
8
Lentz, Samuel
8
Creasman, William
8
Thigpen, Tate
7
Hanjani, Parviz
6
DeGeest, Koen
6
Markman, Maurie
6
Muss, Hyman
6
Sorosky, Joel
6
Waggoner, Steven
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of John Blessing (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Miller David Scott; Blessing John A; Drake Richard D; Higgins Robert; McMeekin D Scott; Puneky Louis V; Krasner Carolyn N
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Gynecologic oncology 2009;115(3):443-6.
-
2009: Aghajanian Carol; Blessing John A; Darcy Kathleen M; Reid Gary; DeGeest Koen; Rubin Stephen C; Mannel Robert S; Rotmensch Jacob; Schilder Russell J; Riordan William;
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2009;115(2):215-20.
-
2009: Miller David S; Blessing John A; Krasner Carolyn N; Mannel Robert S; Hanjani Parviz; Pearl Michael L; Waggoner Steven E; Boardman Cecelia H
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2686-91.
-
2008: Garcia Agustin A; Blessing John A; Nolte Susan; Mannel Robert S;
A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
Gynecologic oncology 2008;111(1):22-6.
-
2008: Miller David Scott; Blessing John A; Bodurka Diane C; Bonebrake Albert J; Schorge John O;
Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2008;110(1):65-70.
-
2007: Garcia Agustin A; Blessing John A; Vaccarello Luis; Roman Lynda D;
Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
American journal of clinical oncology 2007;30(4):428-31.
-
2007: Garcia Agustin A; Blessing John A; Darcy Kathleen M; Lenz Heinz Josef; Zhang Wu; Hannigan Ed; Moore David H
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Gynecologic oncology 2007;104(3):572-9.
-
2006: Fracasso Paula M; Blessing John A; Molpus Kelly L; Adler Lisa M; Sorosky Joel I; Rose Peter G
Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2006;103(2):523-6.
-
2006: Brewer Cheryl A; Blessing John A; Nagourney Robert A; Morgan Mark; Hanjani Parviz
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2006;103(2):446-50.
-
2006: Rose Peter G; Blessing John A; Lele Shashikant; Abulafia Ovadia
Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2006;102(2):210-3.
-
2006: Markman Maurie; Blessing John; Rubin Stephen C; Connor Joseph; Hanjani Parviz; Waggoner Steven
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
Gynecologic oncology 2006;101(3):436-40.
-
2006: Brewer Cheryl A; Blessing John A; Nagourney Robert A; McMeekin D Scott; Lele Shashikant; Zweizig Susan L
Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2006;100(2):385-8.
-
2005: Miller David Scott; Blessing John A; Schilder Jeanne; Munkarah Adnan; Lee Yi Chun
Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Gynecologic oncology 2005;98(2):217-21.
-
2005: Homesley Howard D; Blessing John A; Sorosky Joel; Reid Gary; Look Katherine Y
Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
Gynecologic oncology 2005;98(2):294-8.
-
2005: Garcia Agustin A; Blessing John A; Lenz Heinz-Josef; Darcy Kathleen M; Mannel Robert S; Miller David Scott; Husseinzadeh Nader;
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Gynecologic oncology 2005;96(3):810-7.
-
2005: Sutton Gregory; Blessing John; Hanjani Parviz; Kramer Paul;
Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Gynecologic oncology 2005;96(3):749-52.
-
2005: Muggia Franco M; Blessing John A; Waggoner Steven; Berek Jonathan S; Monk Bradley J; Sorosky Joel; Pearl Michael L
Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.
Gynecologic oncology 2005;96(1):108-11.
-
2005: Schilder Russell J; Blessing John; Cohn David E
Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2005;96(1):103-7.
-
2005: Miller David Scott; Blessing John A; Waggoner Steven; Schilder Jeanne; Sorosky Joel; Bloss Jeffrey; Schilder Russell
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Gynecologic oncology 2005;96(1):67-71.
-
2004: Morris Mitchell; Blessing John A; Monk Bradley J; McGehee Ramon; Moore David H
Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3340-4.
-
2004: Muggia Franco M; Blessing John A; McGehee Ramon; Monk Bradley J
Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2004;94(2):483-7.
-
2004: Moore David H; Blessing John A; McQuellon Richard P; Thaler Howard T; Cella David; Benda Jo; Miller David S; Olt George; King Stephanie; Boggess John F; Rocereto Thomas F
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3113-9.
-
2004: Schilder Russell J; Blessing John A; Pearl Michael L; Rose Peter G
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
Investigational new drugs 2004;22(3):343-9.
-
2004: Tate Thigpen J; Blessing John A; DeGeest Koen; Look Katherine Y; Homesley Howard D;
Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study.
Gynecologic oncology 2004;93(2):336-9.
-
2004: Look Katherine Y; Sandler Alan; Blessing John A; Lucci Joseph A; Rose Peter G;
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.
Gynecologic oncology 2004;92(2):644-7.
-
2004: Muggia Franco M; Blessing John A; Method Michael; Miller David Scott; Johnson Gary A; Lee Roger B; Menzin Andrew;
Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Gynecologic oncology 2004;92(2):639-43.
-
2003: Miller David Scott; Blessing John A; Lentz Samuel S; McMeekin D Scott
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
Cancer 2003;98(8):1664-9.
-
2003: Thigpen J Tate; Blessing John A; Olt George; Lentz Samuel S; Bell Jeffrey
Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study.
Gynecologic oncology 2003;90(3):581-6.
-
2003: Fracasso Paula M; Blessing John A; Morgan Mark A; Sood Anil K; Hoffman James S
Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2856-9.
-
2003: Fracasso Paula M; Blessing John A; Wolf Judith; Rocereto Thomas F; Berek Jonathan S; Waggoner Steven
Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Gynecologic oncology 2003;90(1):177-80.
-
2003: Rose Peter G; Blessing John A; Buller Richard E; Mannel Robert S; Webster Kenneth D
Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Gynecologic oncology 2003;89(2):267-70.
-
2003: Hoffman Mark A; Blessing John A; Lentz Samuel S;
A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2003;89(1):95-8.
-
2003: Gallup Donald G; Blessing John A; Andersen Willie; Morgan Mark A;
Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.
Gynecologic oncology 2003;89(1):48-51.
-
2003: Lincoln Sarah; Blessing John A; Lee Roger B; Rocereto Thomas F
Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2003;88(3):277-81.
-
2003: Rose Peter G; Blessing John A; Ball Harrison G; Hoffman James; Warshal David; DeGeest Koen; Moore David H
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2003;88(2):130-5.
-
2002: Miller David Scott; Blessing John A; Lentz Samuel S; Waggoner Steven E
A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
Gynecologic oncology 2002;87(3):247-51.
-
2002: Plaxe Steven C; Blessing John A; Olt George; Husseinzadah Nader; Lentz Samuel S; DeGeest Koen; Valea Fidel A
A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Cancer chemotherapy and pharmacology 2002;50(2):151-4.
-
2002: Muggia Franco M; Blessing John A; Sorosky Joel; Reid Gary C
Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2360-4.
-
2002: Fowler Jeffrey M; Blessing John A; Burger Robert A; Malfetano John H
Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.
Gynecologic oncology 2002;85(2):311-4.
-
2002: Bloss Jeffrey D; Blessing John A; Behrens Brent C; Mannel Robert S; Rader Janet S; Sood Anil K; Markman Maurie; Benda Jo
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1832-7.
-
2002: Plaxe Steven C; Blessing John A; Morgan Mark A; Carlson John;
Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.
American journal of clinical oncology 2002;25(1):45-7.
-
2002: Plaxe Steven C; Blessing John A; Husseinzadeh Nader; Webster Kenneth D; Rader Janet S; Dunton Charles J
Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gynecologic oncology 2002;84(2):241-4.
-
2002: Smith Harriet O; Blessing John A; Vaccarello Luis
Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2002;84(1):140-4.
-
2002: Plaxe Steven C; Blessing John A; Bookman Michael A; Creasman William T
Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2002;84(1):32-5.
-
2001: Curtin J P; Blessing J A; Soper J T; DeGeest K
Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
Gynecologic oncology 2001;83(2):268-70.
-
2001: Hurteau J A; Blessing J A; DeCesare S L; Creasman W T
Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study.
Gynecologic oncology 2001;82(1):7-10.
-
2001: Hoffman M A; Blessing J A; Nuñez E R
A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2001;81(3):433-5.
-
2001: Muderspach L I; Blessing J A; Levenback C; Moore J L
A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Gynecologic oncology 2001;81(2):213-5.
-
2001: Curtin J P; Blessing J A; Webster K D; Rose P G; Mayer A R; Fowler W C; Malfetano J H; Alvarez R D
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1275-8.
-
2001: Plaxe S C; Blessing J A; Lucci J A; Hurteau J A
A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
Investigational new drugs 2001;19(1):77-80.
-
2000: Hoffman M A; Blessing J A; Morgan M
Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
Gynecologic oncology 2000;79(3):463-5.
-
2000: Mannel R S; Blessing J A; Boike G
Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group.
Gynecologic oncology 2000;79(1):64-6.
-
2000: Miller D S; Blessing J A; Kilgore L C; Mannel R; Van Le L
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
American journal of clinical oncology 2000;23(4):355-7.
-
2000: Bookman M A; Blessing J A; Hanjani P; Herzog T J; Andersen W A
Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2000;77(3):446-9.
-
2000: Markman M; Blessing J A; Alvarez R D; Hanjani P; Waggoner S; Hall K
Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
Gynecologic oncology 2000;77(1):112-5.
-
2000: McGuire W P; Blessing J A; Bookman M A; Lentz S S; Dunton C J
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):1062-7.
-
2000: Schilder R J; Blessing J A; Morgan M; Mangan C E; Rader J S
Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group.
Gynecologic oncology 2000;76(2):204-7.
-
1999: Moore D H; Blessing J A; Dunton C; Buller R E; Reid G C
Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 1999;75(3):473-5.
-
1999: Markman M; Blessing J A; DeGeest K; Morgan M; Look K Y; Herzog T J; Rose P G
Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Gynecologic oncology 1999;75(3):444-6.
-
1999: Rose P G; Blessing J A; Gershenson D M; McGehee R
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2676-80.
-
1999: Sutton G; Blessing J A; Ball H
Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.
Gynecologic oncology 1999;74(3):346-9.
-
1999: Berek J S; Markman M; Blessing J A; Kucera P R; Nelson B E; Anderson B; Hanjani P
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
Gynecologic oncology 1999;74(1):48-52.
-
1998: Look K Y; Blessing J A; Nelson B E; Johnson G A; Fowler W C; Reid G C
A phase II trial of isotretinoin and alpha interferon in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
American journal of clinical oncology 1998;21(6):591-4.
-
1998: Look K Y; Blessing J A; Levenback C; Kohler M; Chafe W; Roman L D
A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
Gynecologic oncology 1998;70(3):334-8.
-
1998: Rose P G; Blessing J A; Soper J T; Barter J F
Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Gynecologic oncology 1998;70(2):267-71.
-
1998: Rose P G; Blessing J A; Van Le L; Waggoner S
Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Gynecologic oncology 1998;70(2):263-6.
-
1998: Asbury R; Blessing J A; Reid G C; McGuire W P
A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
American journal of clinical oncology 1998;21(4):406-7.
-
1998: Markman M; Blessing J A; Moore D; Ball H; Lentz S S
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Gynecologic oncology 1998;69(3):226-9.
-
1998: Asbury R; Blessing J A; Podczaski E; Ball H
A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
American journal of clinical oncology 1998;21(3):306-7.
-
1998: Asbury R; Blessing J A; Buller R; Malfetano J H; Walker J; Sevin B U
Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.
American journal of clinical oncology 1998;21(2):145-6.
-
1998: Rose P G; Blessing J A; Mayer A R; Homesley H D
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):405-10.
-
1998: Manetta A; Blessing J A; Hurteau J A
Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group.
Gynecologic oncology 1998;68(1):45-6.
-
1998: Muggia F M; Blessing J A; Homesley H D; Sorosky J
Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group.
Cancer chemotherapy and pharmacology 1998;42(1):68-70.
-
1997: Look K Y; Blessing J A; Valea F A; McGehee R; Manetta A; Webster K D; Andersen W A
Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.
Gynecologic oncology 1997;67(3):255-8.
-
1997: Asbury R; Blessing J A; Look K Y; Buller R; Lucci J A
A phase II trial of amonafide in patients with nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
American journal of clinical oncology 1997;20(6):626-7.
-
1997: Lincoln S; Blessing J A; McGehee R; Lentz S S
Phase II trial of piroxantrone in advanced squamous cell carcinoma of the cervix: a Gynecological Oncology Group study.
American journal of clinical oncology 1997;20(1):84-5.
-
1997: Omura G A; Blessing J A; Vaccarello L; Berman M L; Clarke-Pearson D L; Mutch D G; Anderson B
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):165-71.
-
1996: Thigpen T; Blessing J A; Yordan E; Valea F; Vaccarello L
Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Gynecologic oncology 1996;63(1):120-2.
-
1996: Rose P G; Blessing J A; Lewandowski G S; Creasman W T; Webster K D
A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 1996;63(1):101-4.
-
1996: Sutton G P; Blessing J A; DeMars L R; Moore D; Burke T W; Grendys E C
A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
Gynecologic oncology 1996;63(1):25-7.
-
1996: Look K Y; Blessing J A; Gallup D G; Lentz S S
A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
American journal of clinical oncology 1996;19(5):439-41.
-
1996: Sutton G; Blessing J A; Malfetano J H
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
Gynecologic oncology 1996;62(2):226-9.
-
1996: Asbury R; Blessing J A; Moore D
A phase II trail of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: a Gynecologic Oncology Group study.
American journal of clinical oncology 1996;19(4):400-2.
-
1996: Look K Y; Blessing J A; Adelson M D; Morris M; Bookman M A
A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
American journal of clinical oncology 1996;19(1):7-9.
-
1995: Look K Y; Blessing J A; Williams L; Morris M
A phase II trial of merbarone (NSC 336628) as salvage therapy for squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study.
American journal of clinical oncology 1995;18(5):441-3.
-
1995: Asbury R; Blessing J A; Smith D M; Carson L F
Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus. A Gynecologic Oncology Group study.
American journal of clinical oncology 1995;18(5):397-9.
-
1995: Thigpen T; Blessing J A; Gallup D G; Maiman M; Soper J T
Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
Gynecologic oncology 1995;57(3):376-9.
-
1995: Braly P S; Berek J S; Blessing J A; Homesley H D; Averette H
Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
Gynecologic oncology 1995;56(2):164-8.
-
1994: Stehman F B; Blessing J A; Fowler W C; Park R C
Quality assessment and assurance programs in the Gynecologic Oncology Group.
Obstetrics and gynecology 1994;84(6):1059-62.
-
1994: Thigpen J T; Blessing J A; Ball H; Hummel S J; Barrett R J
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(9):1748-53.
-
1994: Thigpen J T; Blessing J A; DiSaia P J; Yordan E; Carson L F; Evers C
A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(7):1408-14.
-
1994: Sutton G P; Blessing J A; Homesley H D; Malfetano J H
A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
Gynecologic oncology 1994;53(1):24-6.
-
1994: Asbury R F; Blessing J A; Soper J T
A Gynecologic Oncology Group phase II study of amonafide (NSC #308847) in squamous cell carcinoma of the cervix.
American journal of clinical oncology 1994;17(2):125-8.
-
1994: Williams S; Blessing J A; Liao S Y; Ball H; Hanjani P
Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):701-6.
-
1994: Williams S D; Blessing J A; DiSaia P J; Major F J; Ball H G; Liao S Y
Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience.
Gynecologic oncology 1994;52(3):287-91.
-
1994: Sutton G P; Blessing J A; Homesley H D; McGuire W P; Adcock L
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Cancer 1994;73(5):1453-5.
-
1994: Sutton G P; Blessing J A; Barrett R J; Gallup D G
Phase II trial of menogaril in patients with squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Gynecologic oncology 1994;52(2):229-31.
-
1993: Asbury R F; Blessing J A; Look K Y; Clarke-Pearson D; Homesley H D
A Gynecologic Oncology Group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer.
American journal of clinical oncology 1993;16(6):529-31.
-
1993: Barrett R J; Blessing J A; Homesley H D; Twiggs L; Webster K D
Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.
American journal of clinical oncology 1993;16(6):494-6.
-
1993: Muss H B; Blessing J A; DuBeshter B
Echinomycin in recurrent and metastatic endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group.
American journal of clinical oncology 1993;16(6):492-3.
-
1993: Markman M; Blessing J A; Major F; Manetta A
Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
Gynecologic oncology 1993;50(2):191-5.
-
1993: Sutton G P; Blessing J A; DiSaia P J; McGuire W P
Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Gynecologic oncology 1993;49(1):48-50.
-
1993: Sutton G P; Blessing J A; McGuire W P; Patton T; Look K Y
Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
American journal of obstetrics and gynecology 1993;168(3 Pt 1):805-7.
-
1993: Major F J; Blessing J A; Silverberg S G; Morrow C P; Creasman W T; Currie J L; Yordan E; Brady M F
Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study.
Cancer 1993;71(4 Suppl):1702-9.
-
1992: Sutton G P; Blessing J A; Manetta A; Homesley H; McGuire W
Gynecologic Oncology Group studies with ifosfamide.
Seminars in oncology 1992;19(6 Suppl 12):31-4.
-
1992: Look K Y; Blessing J A; Muss H B; Partridge E E; Malfetano J H
5-fluorouracil and low-dose leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
American journal of clinical oncology 1992;15(6):497-9.
-
1992: Look K Y; Blessing J A; Muss H B; DeGeest K
5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group.
American journal of clinical oncology 1992;15(6):494-6.
-
1992: Muss H B; Blessing J A; Hanjani P; Malfetano J H; Kemp G M; Webster K
Echinomycin (NSC 526417) in recurrent and metastatic nonsquamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
American journal of clinical oncology 1992;15(4):363-4.
-
1992: Sutton G P; Soper J T; Blessing J A; Hatch K D; Barnhill D R
Ifosfamide alone and in combination in the treatment of refractory malignant gestational trophoblastic disease.
American journal of obstetrics and gynecology 1992;167(2):489-95.
-
1992: Muss H B; Blessing J A; Eddy G L; McGehee R
Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group (GOG).
Investigational new drugs 1992;10(1):25-6.
-
1992: Sutton G P; Blessing J A; Barrett R J; McGehee R
Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
American journal of obstetrics and gynecology 1992;166(2):556-9.
-
1991: Thigpen J T; Blessing J A; Beecham J; Homesley H; Yordan E
Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(11):1962-6.
-
1991: Hatch K D; Beecham J B; Blessing J A; Creasman W T
Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients.
Cancer 1991;68(2):269-71.
-
1991: Slayton R E; Blessing J A; Look K; Anderson B
A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study.
Investigational new drugs 1991;9(2):207-8.
-
1991: Slayton R E; Blessing J A; Clarke-Pearson D
A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group study.
Investigational new drugs 1991;9(1):93-4.
-
1990: Sutton G P; Blessing J A; Barnes W; Ball H
Phase II study of vinblastine in previously treated squamous carcinoma of the cervix. A Gynecologic Oncology Group study.
American journal of clinical oncology 1990;13(6):470-1.
-
1990: Homesley H D; Blessing J A; Schlaerth J; Rettenmaier M; Major F J
Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study.
Gynecologic oncology 1990;39(3):305-8.
-
1990: Sutton G P; Blessing J A; Adelson M D; Hanjani P
Phase II trial of vinblastine in advanced ovarian carcinoma. A Gynecologic Oncology Group study.
Investigational new drugs 1990;8(4):377-9.
-
1990: Muss H B; Blessing J A; Baker V V; Barnhill D R; Adelson M D
Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the Gynecologic Oncology Group.
American journal of clinical oncology 1990;13(4):299-301.
-
1990: Muss H B; Blessing J A; Malfetano J
Echinomycin (NSC 526417) in squamous-cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
American journal of clinical oncology 1990;13(3):191-3.
-
1990: McGuire W P; Blessing J A; Hatch K D; Berman M L
Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced squamous cancer of the cervix. A Gynecologic Oncology Group study.
Investigational new drugs 1990;8(2):195-7.
-
1990: McGuire W P; Blessing J A; Berek J S; Munoz A
Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study.
Investigational new drugs 1990;8(2):191-4.
-
1990: Sutton G P; Blessing J A; Photopulos G; Berman M L; Homesley H D
Gynecologic Oncology Group experience with ifosfamide.
Seminars in oncology 1990;17(2 Suppl 4):6-10.
-
1990: Muss H B; Blessing J A; Hatch K D; Soper J T; Webster K D; Kemp G M
Methotrexate in advanced endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group.
American journal of clinical oncology 1990;13(1):61-3.
-
1990: Asbury R F; Blessing J A; McGuire W P; Hanjani P; Mortel R
Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium. A phase II study of the Gynecologic Oncology group.
American journal of clinical oncology 1990;13(1):39-41.
-
1990: Sutton G P; Blessing J A; Photopulos G; Berman M L; Homesley H D
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Cancer chemotherapy and pharmacology 1990;26 Suppl():S55-8.
-
1989: Stehman F B; Blessing J A; McGehee R; Barrett R J
A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1892-5.
-
1989: Slayton R E; Blessing J A; Rettenmaier M; Ball H
A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent adenocarcinoma and adenosquamous carcinoma of the cervix. A Gynecologic Oncology Group study.
Investigational new drugs 1989;7(4):337-40.
-
1989: McGuire W P; Blessing J A; Berman M L
Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
Investigational new drugs 1989;7(4):333-6.
-
1989: Sutton G P; Blessing J A; Adcock L; Webster K D; DeEulis T
Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.
Investigational new drugs 1989;7(4):341-3.
-
1989: Sutton G P; Blessing J A; Homesley H D; Berman M L; Malfetano J
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(11):1672-6.
-
1989: Asbury R F; Blessing J A; DiSaia P J; Malfetano J
Aminothiadiazole (NSC 4728) in patients with advanced nonsquamous carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
American journal of clinical oncology 1989;12(5):375-7.
-
1989: McGuire W P; Arseneau J; Blessing J A; DiSaia P J; Hatch K D; Given F T; Teng N N; Creasman W T
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(10):1462-8.
-
1989: Bonomi P; Blessing J; Ball H; Hanjani P; DiSaia P J
A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Gynecologic oncology 1989;34(3):357-9.
-
1989: Thigpen J T; Blessing J A; Vance R B; Lambuth B W
Chemotherapy in ovarian carcinoma: present role and future prospects.
Seminars in oncology 1989;16(4 Suppl 6):58-65.
-
1989: Sutton G P; Blessing J A; Rosenshein N; Photopulos G; DiSaia P J
Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
American journal of obstetrics and gynecology 1989;161(2):309-12.
-
1989: McGuire W P; Blessing J A; Yordan E; Beecham J
Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
Investigational new drugs 1989;7(2-3):235-8.
-
1989: Walton L A; Blessing J A; Homesley H D
Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(4):466-70.
-
1989: Thigpen J T; Blessing J A; Homesley H; Creasman W T; Sutton G
Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gynecologic oncology 1989;33(1):68-70.
-
1989: Sutton G P; Stehman F B; Einhorn L H; Roth L M; Blessing J A; Ehrlich C E
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(2):223-9.
-
1989: Thigpen J T; Blessing J A; DiSaia P J; Fowler W C; Hatch K D
A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
Gynecologic oncology 1989;32(2):198-202.
-
1989: Sutton G P; Blessing J A; Photopulos G; Berman M L; Homesley H D
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Seminars in oncology 1989;16(1 Suppl 3):68-72.
-
1988: Slayton R E; Blessing J A; DiSaia P J; Phillips G
A phase II clinical trial of diaziquone in the treatment of patients with recurrent endometrial carcinoma. A Gynecologic Oncology Group study.
American journal of clinical oncology 1988;11(6):612-3.
-
1988: Thigpen J T; Blessing J A; Ball H; Hanjani P; Manetta A; Homesley H
Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.
Gynecologic oncology 1988;31(3):435-8.
-
1988: Homesley H D; Blessing J A; Rettenmaier M; Capizzi R L; Major F J; Twiggs L B
Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease.
Obstetrics and gynecology 1988;72(3 Pt 1):413-8.
-
1988: Bonomi P; Yordan E; Blessing J A
Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study.
American journal of clinical oncology 1988;11(1):1-2.
-
1987: Thigpen T; Vance R; Lambuth B; Balducci L; Khansur T; Blessing J; McGehee R
Chemotherapy for advanced or recurrent gynecologic cancer.
Cancer 1987;60(8 Suppl):2104-16.
-
1985: Omura G A; Blessing J A; Major F; Lifshitz S; Ehrlich C E; Mangan C; Beecham J; Park R; Silverberg S
A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(9):1240-5.
-
1985: Bonomi P; Blessing J A; Stehman F B; DiSaia P J; Walton L; Major F J
Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(8):1079-85.
-
1984: Stehman F B; Blessing J A; Homesley H D; Currie J L; Yordan E L
Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma. A Gynecologic Oncology Group study.
Investigational new drugs 1984;2(3):331-3.
-
1983: Omura G A; Major F J; Blessing J A; Sedlacek T V; Thigpen J T; Creasman W T; Zaino R J
A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas.
Cancer 1983;52(4):626-32.
-
1981: Thigpen T; Shingleton H; Homesley H; Lagasse L; Blessing J
Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Cancer 1981;48(4):899-903.
-
1981: Thigpen T; Vance R B; Balducci L; Blessing J
Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma.
Cancer 1981;48(2 Suppl):658-65.
Sign-in to see more
